Alpha Cognition Announces Submission of New Drug Application to the FDA for ALPHA-1062 for Mild-to-Moderate Alzheimer ’s Disease

VANCOUVER, B.C., September 27, 2023. Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition“ACI”, or the“Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news